NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE American · Biotechnology · USD

Lineage Cell Therapeutics, Inc. (LCTX) Stock Analysis

Lineage Cell Therapeutics, Inc. (LCTX) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

LCTX

$1.08

−$0.02 (−1.82%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LCTX with… →

LCTX Key Statistics

As of Sep 4, 2026
Trading
Open
$1.09
Previous Close
$1.10
Day's Range
1.08–1.11
52-Week Range
1.00–2.09
Volume
535.70K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.55
Valuation
Market Cap
$273.14M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
10.64
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
20.88
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.19
Financials (FY)
Revenue (FY)
$14.56M+53.24%
Net Income (FY)
−$63.53M
Profit marginThe share of revenue left as profit after all costs and taxes.
−246.58%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
252.91M
1-Year Return
−10.00%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
1.34M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

LCTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−35.33%
2025+234.00%
2024−54.13%
2023−6.84%
2022−52.24%
2021+39.20%
2020+97.75%
2019−2.20%
2018−51.62%
2017−40.44%
2016 (partial year)+8.74%

As of September 4, 2026.

LCTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$14.56M−$63.53M−436.5%
2024$9.50M−$18.61M−195.9%
2023$8.95M−$21.49M−240.2%
2022$14.70M−$26.27M−178.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$14.56M$14.41M−$21.78M−$63.53M−436.5%
2024$9.50M$9.17M−$21.48M−$18.61M−195.9%
2023$8.95M$8.27M−$24.73M−$21.49M−240.2%
2022$14.70M$13.98M−$22.52M−$26.27M−178.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LCTX Valuation vs Biotechnology Median

Median of 656 stocks
MetricLCTXBiotechnology medianvs median
P/S ratio20.8815.2637% above
Profit margin−246.58%0.00%246.6 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Lineage Cell Therapeutics, Inc. (LCTX) is capitalised at $273.14M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 72.

The 52-week range on file runs from $1.00 to $2.09. LCTX last closed at $1.08 on September 4, 2026. That is −$0.02 (−1.82%) against the previous close. The latest close sits 8% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $14.56M. Against the prior fiscal year total of $9.50M, that is a change of +53.24%. The same year closed with a net loss of $63.53M. The reported profit margin is −246.58%. That is 246.6 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −0.19.

Across the 4 fiscal years on file, revenue moves from $14.70M in 2022 to $14.56M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 10.64. The price-to-sales ratio is 20.88. On price-to-sales that is 36.78% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 1.55. Annualized volatility over the trailing 10 years is 75.4%. Over the trailing twelve months the price has returned −10.00%. Across 10 years the annualized return works out at −8.03%.

Growth & Income

The record shows no dividend for LCTX.

So far in 2026 the price is −35.33%. The strongest complete calendar year on file is 2025 at +234.00%; the weakest is 2024 at −54.13%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Lineage Cell Therapeutics, Inc. (LCTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Lineage Cell Therapeutics, Inc. LCTX $273.14M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Lineage Cell Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Visit website →